Skip to main content

Digital Droplet PCR Assay to Measure AAV vector DNA

Droplet digital PCR (ddPCR):
A third generation of quantitative PCR, water and oil emulsions is used to segment the samples and create droplets to identify and quantify the genetic material in the sample. It is a new PCR technique that directly quantifies DNA copies with an unparalleled degree of precision and without the need for a standard curve or for a high degree of amplification efficiency; all properties that lend themselves to the accurate quantification of both single-stranded and self-complementary AAV genomes.

The advantage of ddPCR for the nucleic acid quantification includes: 
  • Unparalleled precision: the massive sample partitioning afforded by ddPCR enables small fold decrease in target DNA sequences between samples to be reliably measured.  
  • Increased signal-to-noise: enrich for rare targets by reducing competition that comes from high-copy templates. 
  • Removal of PCR efficiency bias: error rates are reduced by removing the amplification efficiency reliance of PCR, enabling accurate quantification of targets.
  • Simplified quantification: a standard curve is not required for absolute quantification
The procedure/steps involved for quantification of viral DNA using Bio-rad's ddPCR are:
i) Droplet Generation 
ii) PCR Amplification
iii) Droplet Reading 
iv) ddPCR Data Analysis 



i) Droplet Generation
Before droplet generation, ddPCR reaction are prepared in a similar manner as read-time PCR reactions that use Taq man hydrolysis probes labeled with FAM and HEX (or VIC) reporter flurophores, or an intercalating dye such as EvaGreen.
  • For the droplet generation, assemble the recommended ddPCR supermix (Bio-Rad, Hercules, CA) for preparing the reaction mixtures. 
  • Use the pre-designed TaqMan primers and probes in final optimized concentrations of (~100 nM to 100 nM), and template (5 ÎĽl) in a final volume of 20 ÎĽl. 
  • Load each reaction into the sample well of an eight-well disposable cartridge (Bio-Rad) along with 70 ÎĽl of droplet generation oil (Bio-Rad), and generate droplets in a droplet generator (Bio-Rad). 
  • The droplet generator produces about 20,000 droplets per sample in about 2.5 min for eight samples. 
ii) PCR Amplification
  • Gently pipette and transfer droplets to a 96-well PCR plate and seal the plate with PCR plate sealer and pierceable foil heat seal
  • Amplify the DNA to the end point with a conventional thermal cycler with recommended cycling protocol (95°C for 10 min, followed by 42 cycles of 95°C for 30 sec, 60°C for 1 min, and 72°C for 15 sec followed by a final 98°C heat treatment for 10 min).
iii) Droplet Reading
  • Open the QuantaSoft software in the setup mode and design a new plate with a layout according to the experimental design.
  • Designate the sample name, experiment type, corresponding fluorescence channels such as FAM and HEX.
  • Scan the PCR plate on QX100 droplet reader (Bio-Rad).

iv) ddPCR Data Analysis 
  • Analyze the data with QuantaSoft software.
  • If the plate is set up for absolute quantitation analysis, automatic thresholding determines concentration and populates the data tables in the analysis mode of the software. 
  • The concentration reported is coplies per microliter of the final 1X ddPCR reaction. 
  • The copies per microliter readout from the QX100 reader should be converted to genome copies per milliliter according to the formula:
X=[(aY)(1000/b)]D,
        where X is GC/ml, a is volume of the ddPCR (20 ÎĽl),
        Y is ddPCR readout copies per microliter, 
        b is volume of diluted vector in the ddPCR (5 ÎĽl), and 
        D is total dilution applied to the test material.



References:
Primer and Probe designing for ddPCR/qPCR
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991984/
https://www.bio-rad.com/webroot/web/pdf/lsr/literature/Bulletin_6407.pdf

Popular posts from this blog

Human Genome Editing: FDA Draft Guidance Summary

Consideration for Developing Gene Editing Product  1. Genome Editing Methods: Genome editing can be achieved through nuclease-dependent or nuclease-independent methods. Nuclease-dependent methods involve introducing site-specific breaks in DNA using technologies like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), modified-homing endonucleases, and CRISPR-associated (Cas) nucleases. These breaks can lead to modification of the DNA sequence at the cleavage site. Nuclease-independent methods can change DNA sequences without cleaving the DNA and include techniques like base editing and synthetic triplex-forming peptide nucleic acids. The choice of GE technology should consider factors such as the mechanism of action, the ability to target specific DNA sequences, and the potential to optimize components for efficiency, specificity, or stability. 2. Type and Degree of Genomic Modification: Different GE approaches rely on DNA repair pathways such as ho

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quantification of si

Human Gene Therapy for Neurodegenerative Diseases: FDA Guidance Summary

  Neurodegenerative diseases are a diverse group of disorders characterized by the progressive degeneration of the central or peripheral nervous system, and they can have various causes and clinical characteristics. This guidance document is a resource for sponsors on different aspects of product development, preclinical testing, and clinical trial design. It acknowledges the unique challenges and considerations associated with developing GT products for such complex and varied diseases. Below are the key summaries from the guidance. CONSIDERATIONS FOR CHEMISTRY, MANUFACTURING AND CONTROLS (CMC) The considerations for Chemistry, Manufacturing, and Controls (CMC) when developing gene therapy (GT) products for the treatment of neurodegenerative diseases are crucial for ensuring the safety and efficacy of these advanced therapies. Here, we will elaborate on the specific CMC considerations outlined in your text: Route of Administration and Product Volume: Neurodegenerative diseases often r

FDA Guidance on Studying Multiple Versions of Cellular or Gene Therapy Products in Early-Phase Clinical Trials

 The purpose of this guidance is to offer advice to sponsors interested in conducting early-phase clinical trials for a single disease involving multiple variations of a cellular or gene therapy product. Sponsors aim to gather preliminary safety and efficacy data for these product variations within a single clinical trial. It's important to note that even though multiple product versions are studied together, each version is distinct and typically requires a separate investigational new drug application (IND) submission to the FDA. The primary goal of these early-phase clinical studies is to inform decisions about which product version(s) should be advanced for further development in later-phase trials. As such, these studies are not designed to provide the main evidence of effectiveness needed for a marketing application. They are generally not statistically powered to demonstrate a significant difference in efficacy between the different study arms. In this guidance, the FDA prov

Standard Template For Clinical Study Report (CSR)-Gene Therapy

 A Standard Format for a Clinical Study Report (CSR) typically includes the following sections and components: Title Page: Title of the Clinical Study Report Study Title Protocol Number Version Date Sponsor's Name and Logo Date of Report Compilation Table of Contents: A list of all sections, subsections, and appendices with page numbers for easy navigation. List of Abbreviations and Glossary: A compilation of all abbreviations used throughout the report, along with their definitions. Executive Summary: A concise overview of the study, including objectives, methods, key findings, and conclusions. Introduction: Background and rationale for the study. Study objectives and hypotheses. Study Design and Methods: Detailed information about the study design, including: Inclusion and exclusion criteria. Study population and recruitment. Randomization and blinding procedures. Data collection methods and tools. Statistical analysis plan. Ethical Considerations: Information on ethical approval